{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:27:22Z","timestamp":1760909242462,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12185-020-02929-3","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T10:39:48Z","timestamp":1593599988000},"page":"504-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8057","authenticated-orcid":false,"given":"Koji","family":"Izutsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"2929_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1084\/jem.20020805","volume":"196","author":"E Clayton","year":"2002","unstructured":"Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med. 2002;196:753\u201363.","journal-title":"J Exp Med"},{"key":"2929_CR2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","volume":"297","author":"K Okkenhaug","year":"2002","unstructured":"Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 2002;297:1031\u20134.","journal-title":"Science"},{"key":"2929_CR3","first-page":"1","volume":"347","author":"B Vanhaesebroeck","year":"2010","unstructured":"Vanhaesebroeck B, Vogt PK, Rommel C. PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol. 2010;347:1\u201319.","journal-title":"Curr Top Microbiol Immunol"},{"key":"2929_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cellsig.2010.10.002","volume":"23","author":"WP Fung-Leung","year":"2011","unstructured":"Fung-Leung WP. Phosphoinositide 3-kinase delta (PI3K\u03b4) in leukocyte signaling and function. Cell Signal. 2011;23:603\u20138.","journal-title":"Cell Signal"},{"key":"2929_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"2929_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/cancers9030024","volume":"9","author":"D Gyori","year":"2017","unstructured":"Gyori D, Chessa T, Hawkins PT, Stephens LR. Class (I) phosphoinositide 3-kinases in the tumor microenvironment. Cancers (Basel). 2017;9:24.","journal-title":"Cancers (Basel)"},{"issue":"15 suppl","key":"2929_CR7","doi-asserted-by":"publisher","first-page":"8559","DOI":"10.1200\/jco.2015.33.15_suppl.8559","volume":"33","author":"K Faia","year":"2015","unstructured":"Faia K, Proctor J, Andrade P, et al. High throughput in vitro combination sensitivity screen in hematologic malignancies with the phosphoinositide-3 kinase (PI3K)-delta, gamma inhibitor, duvelisib. J Clin Oncol. 2015;33(15 suppl):8559.","journal-title":"J Clin Oncol."},{"key":"2929_CR8","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","volume":"131","author":"Ian W Flinn","year":"2018","unstructured":"Flinn Ian W, O\u2019Brien Susan, Kahl Brad, et al. Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4, \u03b3, is clinically active in advanced hematologic malignancies. Blood. 2018;131:877\u201387.","journal-title":"Blood"},{"key":"2929_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"2929_CR10","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"Ian W Flinn","year":"2019","unstructured":"Flinn Ian W, Miller Carole B, Ardeshna Kirit M, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J Clin Oncol. 2019;37:912\u201322.","journal-title":"J Clin Oncol"},{"key":"2929_CR11","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"Ian W Flinn","year":"2018","unstructured":"Flinn Ian W, Hillmen Peter, Montillo Marco, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood. 2018;132:2446\u201355.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-02929-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T14:49:38Z","timestamp":1667227778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-02929-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2929"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02929-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"12 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KI reports grants from Abbvie during the conduct of the study; grants and personal fees from Abbvie, Gilead Sciences, Eisai, MSD, Takeda, Janssen, Mundipharma, Chugai, AstraZeneca, Bayer, Ono, Celgene, and Kyowa Kirin outside the submitted work; and personal fees from Bristol Myers Squib, Dainihon Sumitomo, Nihon Mediphysics; grants from Zenyaku, Solasia, Symbio, Astellas, Astellas Amgen, and Daiichi Sankyo outside the submitted work. KK reports grants from AbbVie during the conduct of the study; grants and personal fees from AbbVie, Celgene, Chugai, Eisai, Janssen, Novartis, Takeda, Kyowa-Kirin, and Ono outside the submitted work; and personal fees from AstraZeneca, MSD, Mundi, and Dainippon-Sumitomo outside the submitted work. HK reports grants and personal fees from Daiichi Sankyo, Astellas, and Novartis Pharma outside the submitted work; grants from Chugai Pharmaceutical, Kyowa Kirin, Zenyaku Kogyo, FUJIFILM, Otsuka Pharmaceutical, Takeda Pharmaceutical, Sumitomo Dainippon Pharma, Sanofi, Celgene, Nippon Shinyaku, Eisai, and Pfizer Japan outside the submitted word; and personal fees from Bristol-Myers Squibb, and Amgen Astellas BioPharma outside the submitted work. GY has nothing to disclose. KS reports grants and personal fees from Eisai, Celgene, Chugai Pharmaceutical, Kyowa Kirin, and Daiichi Sankyo outside the submitted work; personal fees from AstraZeneca, Takeda Pharmaceutical, Janssen Pharmaceutical, Bristol-Myers Squibb, and Nippon Shinyaku outside the submitted work; and grants from Otsuka Pharmaceutical, and MSD outside the submitted work. KA reports grants and personal fees from Eisai, Takeda, Janssen, Bristol-Myers Squib, Chugai, Astellas, Daiichi Sankyo, Kyowa Kirin, and Otsuka Pharmaceutical outside the submitted work; personal fees from Abbvie, Celgene, Astellas Amgen, and Novartis outside the submitted work; and grants from Dainihon Sumitomo, Ono, Asahi Kasei Pharma, Shionogi, Yakult, Taiho, Mochida, Japan Blood Products, Nihon Kayaku, Shin Nippon Biomedical, Fujifilm Toyama Chemical, Nippon Shinyaku, Nihon Pharmaceutical, Sanofi, and Otsuka Pharmaceutical Factory outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}